Visual rating scales for age-related white matter changes (leukoaraiosis): Can the heterogeneity be reduced?

Stroke

Volumn 33, Issue 12, 2002, Pages 2827-2833

  Pantoni, Leonardo ^a   Simoni, Michela ^a   Pracucci, Giovanni ^a   Schmidt, Reinhold ^b   Barkhof, Frederik ^c   Inzitari, Domenico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF GRAZ   (Austria)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Leukoaraiosis; Magnetic resonance imaging; Tomography, x ray computed; White matter

Indexed keywords

ADULT; AGED; AGING; ARTICLE; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION FUNCTION; EQUIPMENT; HUMAN; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; VISUAL ANALOG SCALE; WHITE MATTER;

AGING; BRAIN; BRAIN DISEASES; COGNITION DISORDERS; FEASIBILITY STUDIES; GAIT DISORDERS, NEUROLOGIC; HUMANS; HYPERTENSION; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036901352     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000038424.70926.5E     Document Type: Article

References (29)

1. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, Hofman A. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: The Rotterdam Study. Neurology. 1994;44:1246-1252.
2. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Huchinson RG, Tyroler A. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. Stroke. 1996;27:2262-2270.
3. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O'Leary D, Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: The Cardiovascular Health Study. Stroke. 1996;27:1274-1282.
4. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Oftenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-related cerebral damage in the Austrian Stroke Prevention Study. J Neurol Sci. 1997;152:15-21.
5. Hachinski VC, Potter P, Merskey H, Leuko-araiosis. Arch Neurol. 1987;44: 21-23.
6. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report: A review. Stroke. 1995;26:1293-1301.
7. Inzitari D, Romanelli M, Pantoni L. Leukoamiosis and cognitive impairment. In: O'Brien J, Arnes D, Burns A, eds. Dementia. 2nd Ed. London, UK: Edward Arnold Publishers; 2000:635-653.
8. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: A review. Stroke. 1997; 28:652-659.
9. Pantoni L, Leys D, Fazekas F, Longstreth WT Jr, Inzitari D, Wallin A, Filippi M, Scheltens P, Erkinjuntti T, Hachinski V. Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord. 1999; 13(suppl 3):S49-S54.
10. Johnson KA, Davis KR, Buonanno FS, Brady TJ, Rosen TJ, Growdon JH. Comparison of magnetic resonance and roentgen ray computed tomography in dementia. Arch Neurol. 1987;44:1075-1080.
11. Lopez OL, Becker Jr, Jungreis CA, Rezek D, Estol C, Boller F, DeKosky ST. Computed tomography- but not magnetic resonance imaging-identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer's disease. Arch Neurol. 1995;52:659-664.
12. Mäntylä R, Erkinjuntti T, Salonen O, Aronen HJ, Peltonen T, Pohjasvaara T, Standertskjold-Nordenstam C-G. Variable agreement between visual rating scales for white matter hyperintensities on MRI. Stroke. 1997;28:1614-1623.
13. Scheltens Ph, Erkinjuntti T, Leys D, Wahlund L-O, Inzitari D, del Ser T. Pasquier F, Barkhof F, Mäntylä R, Bowler J, Wallin A, Ghika J, Fazekas, F, Pantoni L. White matter changes on CT and MRI: An overview of visual rating scales. Eur Neurol. 1998;39:80-89.
14. Rezek DL, Morris JC, Fulling KH, Gado MH. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology. 1987;37:1365-1368.
15. Van Swieten JC, Hijdra A, Koudstaal PJ, Van Gijn J. Grading white matter lesions on CT and MRI: A simple scale. J Neurol Neurosurg Psychiatry. 1990;53:1080-1083.
16. Blennow K, Wallin A, Uhlemann C, Gottfries GC. White matter lesions on CT in Alzheimer patients: Relation to clinical symptomatology and vascular factors. Acta Neurol Stand. 1991;83:187-193.
17. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJNR Am J Neuroradiol. 1987;8:421-426.
18. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJP, Verrnersch P, Steinling M, Valk J. A semiquantitave rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993; 114:7-12.
19. Ylikoski R, Ylikoski A, Erkinjuntti T, Sulkava R, Raininko R, Tilvis R. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol. 1993;50:818-824.
20. Manolio TA, Kronmal RA, Burke GL, Poirier V, O'Leary DH, Gardin JM, Fried L, Steinberg EP, Bryan RN, for the Cardiovascular Health Study Collaborative Research Group. Magnetic resonance abnormalities and cardiovascular disease in older adults: The ARIC study. Stroke. 1994;25: 318-327.
21. Leys D, Soetaert G, Petit H, Fauquette A, Pruvo JP, Steinling M. Periventricular and white matter magnetic resonance imaging hyperintensities do not differ between Alzheimer's disease and normal aging. Arch Neurol. 1990; 47:524-527.
22. Kozachuk WE, DeCarli C, Schapiro MB, Wagner EE, Rapoport SI, Horwitz B. White matter hyperintensities in dementia of Alzheimer's type and in healthy subjects without cerebrovascular risk factors: A magnetic resonance imaging study. Arch Neurol. 1990;47:1306-1310.
23. Kittner B. Clinical trials of propentofylline in vascular dementia: European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord. 1999; 13(suppl 3):S166-S171.
24. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin A. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci. 2000;175:124-134.
25. Rossi R, Inzitari D, Pantoni L, del Ser T, Erkinjuntti T, Wallin A, Bianchi C, Badenas JM, Beneke M. Nimodipine in subcortical vascular dementia trial. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S159-S165.
26. Scheltens P, Kittner B. Preliminary results from an MRI/CT-based database for vascular dementia and Alzheimer's disease. Ann N Y Acad Sci. 2000;903: 542-546.
27. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181.
28. Fazekas F, Barkhof F, Wahlund L-O, Pantoni L, Erkinjuntti T, Scheltens P, Schmidt R. CT and MRI rating of white-matter lesions. Cerebrovasc Dis. 2002;13(suppl 2):31-36.
29. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318-1322.